Cochrane · systematic review · CD008202
Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in children
Brodlie, M, Gupta, A, Rodriguez‐Martinez, CE, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
8
No studies
2
Included studies
NR
No studies 2 · 20%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 8 · 80%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Maintenance LTRA compared to placebo for episodic viral wheeze in children
Population: episodic viral wheeze in children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants experiencing one or more episode requiring treatment with oral steroids Maintenance LTRA vs placebo | OR 1.2 [0.7, 2.06] | 1 study · 347 participants | Moderate |
Number of participants experiencing one or more episodes requiring ED visit Maintenance LTRA vs placebo | OR 0.66 [0.37, 1.2] | 1 study · 347 participants | Moderate |
Number of participants experiencing one or more episodes requiring hospital admission Maintenance LTRA vs placebo | OR 0.65 [0.23, 1.87] | 1 study · 347 participants | Moderate |
Withdrawals ‐ Total number of withdrawals Maintenance LTRA vs placebo | OR 0.87 [0.66, 1.13] | 2 studies · 1729 participants | Moderate |
Serious adverse events Maintenance LTRA vs placebo | no estimate extracted | NR | No studies |
Intermittent LTRA compared to placebo for episodic viral wheeze in children
Population: episodic viral wheeze in children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants experiencing one or more episode requiring treatment with oral steroids Intermittent LTRA vs placebo | RR 0.85 [0.64, 1.14] | 2 studies · 343 participants | Moderate |
Number of participants experiencing one or more episodes requiring ED visit Intermittent LTRA vs placebo | OR 1 [0.49, 2.02] | 1 study · 141 participants | Moderate |
Number of participants experiencing one or more episodes requiring hospital admission Intermittent LTRA vs placebo | OR 0.73 [0.2, 2.73] | 1 study · 141 participants | Moderate |
Withdrawals ‐ Total number of withdrawals Intermittent LTRA vs placebo | OR 1.03 [0.79, 1.35] | 2 studies · 1402 participants | Moderate |
Serious adverse events Intermittent LTRA vs placebo | no estimate extracted | NR | No studies |